Vivos Therapeutics
Oral-appliance therapy, sleep testing and clinical-practice support for obstructive sleep apnea.
Something off on this page? Send us feedback.
Profile
Sells oral appliances and delivers sleep-testing and treatment services for obstructive sleep apnea, combining devices with clinical support, billing and practice-management services. The model is shifting from training independent dental providers to owned or managed practices supported through management-service structures.
Combines C.A.R.E. oral appliances—custom DNA, mRNA and mmRNA devices—with VivoScore home sleep testing, clinical protocols and adjunctive therapies for breathing-related sleep disorders, principally obstructive sleep apnea. MyoSync provides orofacial myofunctional therapy, while billing and practice-management tools support treatment delivery.
Expanding from training independent dental providers into operating and managing medical sleep practices. Sleep and Airway Medicine Centers use medical, dental, clinical-assistant, administrative and patient-navigation roles; owned or managed operations are concentrated in Nevada and Michigan, and the United States is the principal market.
Earns service revenue from sleep testing, treatment centers, billing, therapy and legacy provider programs, alongside appliance and tooth-positioner sales. The MSO/DSO model requires clinical functions to remain with licensed professional entities and depends on compliance with state practice, fee-splitting, anti-kickback and independent-judgment rules.
Company facts
Categories
Key statistics
Year to date −91.1% · Average volume (30d) 2.7M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior target | Target |
|---|---|---|---|---|
| Apr 17, 2026 | H.C. Wainwright | Target | $2.50 | |
| Apr 17, 2026 | Industrial Alliance Securities | Target | $2.25 | $1.75 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 14, 2026Q2 FY26 | −$0.41 | −$0.31 | +24.4% | $5.6M | $5.2M | −8.5% | −12.26% |
| May 20, 2026Q1 FY26 | −$0.45 | −$0.52 | −15.6% | $4.3M | $5.1M | +18.2% | −0.88% |
| Apr 15, 2026Q1 FY26 | −$0.50 | −$0.58 | −17.2% | $7.1M | $3.8M | −46.1% | −25.85% |
| Nov 19, 2025Q3 FY25 | −$0.53 | −$0.49 | +7.5% | $7.1M | $6.8M | −4.4% | −10.17% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $3.0M | $3.8M | $6.8M | $3.8M | $5.1M | $5.2M | |
| Gross profit | $1.5M | $2.1M | $3.9M | $3.0M | $2.6M | $3.0M | |
| Operating income | −$3.9M | −$4.9M | −$4.7M | −$6.4M | −$6.6M | −$4.8M | |
| Net income | −$3.9M | −$5.0M | −$5.4M | −$7.0M | −$7.8M | −$5.5M | |
| Diluted EPS | −$0.45 | −$0.55 | −$0.49 | −$0.74 | −$0.52 | −$0.31 | |
| Gross margin | 50.0% | 55.2% | 58.0% | 78.1% | 50.7% | 57.3% | |
| Operating margin | -129.9% | -127.4% | -69.8% | -166.9% | -128.7% | -93.6% |
Fiscal years (4-quarter sums)FY21 $16.9M · FY22 $16.0M · FY23 $13.8M · FY24 $15.0M · FY25 $17.4M
Revenue by product · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $1.8M · Total debt $12.1M · Total assets $24.1M · Shareholders' equity −$3.8M
Dividends
No dividends on record.
Ownership
Shares outstanding 13.89M · Float 10.46M · 75.3% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| SP Manager LLC | 2.78M | 19.90% | 13D | Jul 15, 2026 |
| V-Co Investors 3 LLC · 10 percent owner | 1.35M | 9.74% | Form 4 | Apr 10, 2026 |
| Armistice Capital, LLC | 1.12M | 8.27% | 13G | May 15, 2026 |
| Skaff Michael C · 10 percent owner | 1.04M | 7.52% | Form 4 | Apr 2, 2026 |
| Dawei Luo | 572.0K | 8.52% | 13G | Jul 14, 2025 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jun 30, 2026 | Michael C. Skaff | 10 percent owner | +5,498,660 | $0.4560 |
| Mar 31, 2026 | Michael C. Skaff | 10 percent owner | +5,350,746 | $1.07 |
Peers
- ResMed
PAP devices and connected diagnostics contend for OSA patients.
- Inspire Medical Systems
Implantable neurostimulation alternative for moderate-to-severe OSA.
- Nyxoah
Bilateral HGNS option for PAP-intolerant moderate-to-severe OSA.
- Eli Lilly
Drug alternative for obese adults with moderate-to-severe OSA.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Vivos Therapeutics | $0.2250 | +0.31% | $3.1M | — | — | 0.1 | +34.9% |
| ResMed | $240.33 | +0.01% | $34.86B | 23.1 | 19.8 | 6.2 | +8.6% |
| Inspire Medical Systems | $61.44 | −0.11% | $1.78B | 13.3 | 47.3 | 2.0 | −7.6% |
| Nyxoah | $1.59 | −0.90% | $160.1M | — | — | 6.1 | +455.6% |
| Eli Lilly | $1,173.00 | −0.08% | $1.10T | 39.4 | 28.7 | 13.9 | +47.7% |
| Median | 23.1 | 28.7 | 6.1 | +28.1% |